alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › dpp-4-inhibitors

dpp-4-inhibitors

4 studies tagged dpp-4-inhibitors, dated 2022-01-28 to 2025-10-11. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Ocular Complications of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in T2DM Treatments: A Retrospective Real-World Cohort Study 2025-10-11
  2. GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy 2023-11-12
  3. Neuroprotective Role of DPP-4 Inhibitor Linagliptin Against Neurodegeneration, Neuronal Insulin Resistance and Neuroinflammation Induced by Intracerebroventricular Streptozotocin in Rat Model of Alzheimer's Disease 2023-04-20

Studies

4 studies carry this tag.

Date range

2022 to 2025

Top journals

  • Biomedicines 1
  • Clinical pharmacology and therapeutics 1
  • Neurochemical research 1
  • Phytotherapy research : PTR 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Ocular Complications of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in T2DM Treatments: A Retrospective Real-World Cohort Study

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Clinical pharmacology and therapeutics 2025-10-11 Drug development

    Glaucoma is a leading cause of irreversible vision loss worldwide, and type 2 diabetes mellitus (T2DM) is increasingly recognized as a risk factor for glaucoma.

  2. GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer's Disease Therapy

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Biomedicines 2023-11-12 Drug development

    Alzheimer's is a prevalent, progressive neurodegenerative disease marked by cognitive decline and memory loss.

  3. Neuroprotective Role of DPP-4 Inhibitor Linagliptin Against Neurodegeneration, Neuronal Insulin Resistance and Neuroinflammation Induced by Intracerebroventricular Streptozotocin in Rat Model of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neurochemical research 2023-04-20 Drug development

    Alzheimer's disease (AD) is an age-related, multifactorial progressive neurodegenerative disorder manifested by cognitive impairment and neuronal death in the brain areas like hippocampus, yet the precise neuropathology of AD is still unclear.

  4. A novel DPP-4 inhibitor Gramcyclin A attenuates cognitive deficits in APP/PS1/tau triple transgenic mice via enhancing brain GLP-1-dependent glucose uptake

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Phytotherapy research : PTR 2022-01-28 Drug development

    Enhancing glucagon-like peptide 1 (GLP-1) signaling with a dipeptidyl peptidase IV (DPP-4) inhibitor might exert protective effects on Alzheimer's disease (AD).

All topic tags with their study counts